



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Agrawal et al.

Serial No.:

09/825,489

Examiner: Not Yet Assigned

Filed:

April 3, 2001

Group Art Unit:

For:

SENSITIZATION OF CELLS TO CYTOXIC AGENTS USING

OLIGONUCLEOTIDES DIRECTED TO NUCLEOTIDE EXCISION

REPAIR OR TRANSCRIPTION COUPLED REPAIR GENES

Assistant Commissioner for Patents

Washington, D.C. 20231

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

Date

9/10/01

Melanie Legare

The asie Legare

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants and their attorney are aware of the following publications and information listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration.

This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art. If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

U.S.S.N. 09/825,489 Agrawal et al. Page 2

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits and is therefore submitted as both timely and proper; therefore, no fees are believed to be due.

The Commissioner, however, is hereby authorized to charge any fee deficiency or credit any overpayment to Deposit Account No. <u>08-0219</u>.

Respectfully submitted,

Date: Sept. 10, 2001

Ann-Louise Kerner, Ph.D. Registration No. 33,523

Attorney for Applicant

Hale and Dorr LLP 60 State Street Boston, Massachusetts 02109

Tel: (617) 526-6192 Fax: (617) 526-5000



by bt. Form PTO-1449

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 47508.514

Application Number 09/825,489

Applicant
Agrawal et al.

Filing Date

Group Art Unit

Sheet 1 OF

April 3, 2001

		U	.S. Patent Documen	nts		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,235,871	11/25/80	Papahadjopoulos et al.	424	19	
	4,501,728	02/26/85	Geho et al.	424	38	
	4,737,323	04/12/88	Martin et al.	264	4.3	
	4,837,028	06/06/89	Allen	424	450	
	5,149,798	09/22/92	Agrawal et al.	536	27	
	5,366,878	11/22/94	Pederson et al.	435	91.3	
	5,635,377	06/03/97	Pederson et al.	435	91.3	
	5,652,355	07/29/97	Metelev et al.	536	24.5	
	5,652,356	07/29/97	Agrawal	536	245	


3

Foreign Patent Documents							
EXAMINER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL	NUMBER	DATE	COUNTRY			YES	NO
Ī							
					1 !		i

		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
	A1	Chan et al. (1981) "Cross-Sensitivity of Certain Xeroderma Pigmentosum and Cokayne Syndrome Fibroblast Strains to Both Ionizing Radiation and Ultraviolet Light," <i>Mol. Gen. Genet.</i> 181:562-563
į	A2	Deschavanne et al. (1984)"Abnormal Sensitivity of Some Cockayne's Syndrome Cell Strains to UV- and γ-Rays," <i>Mutat. Res.</i> 131:61-70
	АЗ	van Duin et al. (1986) "Molecular Characterization of the Human Excision Repair Gene ERCC-1: cDNA Cloning and Amino Acid Homology With The Yeast DNA Repair Gene RAD10," Cell 44:913-923
	A4	Froehler (1986) "Deoxynucloside H-Phosphonate Diester Intermediates in the Synthesis of Internucleotide Phosphate Analogues," <i>Tetrehedron Lett.</i> 27:5575-5578
	A5	Agrawal et al. (1987) "Oligodeoxynucleoside Methylphosphonates: Synthesis and Enzymatic Degradation," Tetrahedron Lett. 28(31):3539-3542
	A6	Caruthers et al. (1987) "Chemical Synthesis of Deoxyoligonucleotides by the Phosphoramidite Method," Meth. Enzymol. 154:287-313
	A7	Agrawal et al. (1988) "Oligodeoxynucleoside Phosphoramidates and Phosphorothioates as Inhibitors of Human Immunodeficiency Virus," <i>Proc. Natl. Acad.Sci.USA</i> 85:7079-7083
	A8	Eastman et al. (1988) "Enhanced DNA Repair as a Mechanism of Resistance to <i>cis</i> -Diamminedichloroplatinum (II)," <i>Biochem.</i> 27:4730-4734
	A9	Uhlmann et al. (1990) "Antisense Oligonucleotides: A New Therapeutic Principle," Chem. Rev. 90:543-584
/	A10	Coverly et al. (1991) "Requirement for the Replication of Protein in Human DNA Excision Repair," <i>Nature</i> 349:538-541
	A11	Jones et al. (1991) "Gene-Specific Formation and Repair of Cisplatin Intrastrand Adducts and Interstrand Cross- Links in Chinese Hamster Ovary Cells," <i>J. Biol. Chem.</i> 266:7101-7107
	A12	Agrawal (1992) "Antisense Oligonucleotides as Antiviral Agents," Trends. Biotechnol. 10:152-158
1	A13	Barnes et al. (1992) "Mutations in the DNA Ligase I Gene of an Individual With Immunodeficiencies and Cellular Hypersensitivity to DNA-Damaging Agents," Cell 69:495-503

EXAMINER	DATE CONSIDERED		
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.			

BOSTON 1245668v1



Docket Number 47508.514

Application Number 09/825,489

Applicant
Agrawal et al.

Filing Date


Group Art Unit

Sheet	2	OF	3	April 3, 2001

	A14	Bergot et al. (1992) "Separation of Synthetic Phosphorothioate Oligodeoxynucleotides From Their Oxygenated (Phosphodiester) Defect Species by Strong-Anion-Exchange High-Performance Liquid Chromatography," <i>J. Chromatog.</i> 559:35-42
	A15	Troelstra et al. (1992) "ERCC6, A Member of a Subfamily of Putative Helicases, Is Involved in Cockayne's Syndrome and Preferential Repair of Active Genes," <i>Cell</i> 71:939-953
	A16	Zhen et al. (1992) "Increased Gene-Specific Repair of Cisplatin Interstrand Cross-Links in Cisplatin-Resistant Human Ovarian Cancer Cell Lines," <i>Mol. Cell Biol.</i> 12:3689-3698
6	A17	Leadon et al. (1993) "Preferential Repair of Ionizing Radiation-Induced Damage in the Transcribed Strand of an Active Human Gene is Defective in Cockayne Syndrome," <i>Proc. Natl. Acad. Sci. USA</i> 90:10499-10503
	A18	Pon (1993) "Solid-Phase Supports for Oligonucleotide Synthesis," Meth. Mol. Biol. 20:465-496
1	A19	Arteaga et al. (1994) "p185, c-eith-2 Signaling Enhances Cisplatin-Induced Cytotoxicity in Human Breast Carcinoma Cells: Association Between an Oncogenic Receptor Tyrosine Kinase and Drug-Induced DNA Repair," Can. Res. 54:3758-3765
1	A20	Chao (1994) "Enhanced Excision Repair of DNA Damage Due to <i>cis</i> -diamminedichloroplatinum (II) in Resistant Cervix Carcinoma HeLa Cells" <i>Eur. J. Pharmacol.</i> 268:347-355
-	A21	Masutani et al. (1994) "Purification and Cloning of a Nucleotide Excision Repair Complex Involving the Xeroderma Pigmentosum Group C Protein and a Human Homologue of Yeast RAD23, ," <i>EMBO J.</i> 13:1831-1843
	A22	Pietras et al. (1994)" Antibody to HER-2/neu Receptor Blocks DNA Repair After Cisplatin in Human Breast and Ovarian Cancer Cells," Oncogene 9:1829-1838
	A23	Prigent et al. (1994) "Aberrant DNA Repair and DNA Replication Due to an Inherited Enzymatic Defect in Human DNA Ligase I," <i>Mol. Cell Biol.</i> 14:310-317
-	A24	Agrawal et al. (1995) "Modified Oligonucleotides As Therapeutic and Diagnostic Agents," Curr. Opin. Biotechnol. 6:12-19
	A25	Henning et al. (1995) "The Cockayne Syndrome Group A Gene Encodes a WD Repeat Protein That Interacts With CSB Protein and a Subunit of RNA Polymerase II TFIIH," Cell 82:555-564
	A26	Zeng-Rong et al. (1995) "Elevated DNA Repair Capacity is Associated With Intrinsic Resistance of Lung Cancer to Chemotherapy," Can. Res. 55:4760-4764
	A27	Zhao et al. (1995) "Use of Cyclodextrin and Its Derivatives as Carriers for Oligonucleotide Delivery," <i>Antisense Res. Dev.</i> 5:185-192
	A28	Smith et al. (1996) "Antisense GADD45 Expression Results in Decreased DNA Repair and Sensitizes Cells to u.v Irradiation or Cisplatin," <i>Oncogene</i> 13:2255-2263
	A29	States et al. (1996) "Enhanced XPA mRNA Levels in Cisplatin-Resistant Human Ovarian Cancer Are Not Associated With XPA Mutations or Gene Amplification," Can. Lett. 108:233-237
	A 30	Chao (1996) "Cross-Resistance to <i>cis</i> -Diamminedichloroplatinum(II) Of A Multidrug-Resistant Lymphoma Cell Line Associated With Decreased Drug Accumulation and Enhanced DNA Repair," <i>Eur. J. Pharmacol.</i> 305:213-222
	A31	Budd et al. (1997) "The Roles of the Eukaryotic DNA Polymerases in DNA Repair Synthesis," <i>Mutat. Res.</i> 384:157-167
	A32	Hindges et al. (1997) "DNA Polymerase δ, an Essential Enzyme For DNA Transactions," Biol. Chem. 378:345-362
	A33	Jonsson et al. (1997) "Proliferating Cell Nuclear Antigen: More Than A Clamp for DNA Polymerases," <i>BioEssays</i> 19:967-975
	A34	Potapova et al. (1997) "The Jun Kinase/Stress-Activated Protein Kinase Pathway Functions to Regulate DNA Repair and Inhibition of the Pathway Sensitizes Tumor Cells to Cisplatin," <i>J. Biol. Chem.</i> 272:14041-14044
	A35	Wood (1997) "Nucleotide Excision Repair in Mammalian Cells," J. Biol. Chem. 272:23465-23468
-4	A36	Wood et al. (1997)"Which DNA Polymerases Are Used for DNA-Repair in Eukaryotes?" Carcinogenesis 18:605-610
	A37	Lokich et al. (1998) "Carboplatin <i>versus</i> Cisplatin in Solid Tumors: An Analysis of the Literature," <i>Ann. Oncol.</i> 9:13-21
	A38	Mullenders (1998) "Transcription Response and Nucleotide Excision Repair," Mutat. Res. 409:59-64
	A39	Perez (1998) "Cellular and Molecular Determinants of Cisplatin Resistance," Eur. J. Can. 34:1535-1542
	A40	Raymond et al. (1998) "Oxaliplatin: A Review of Preclinical and Clinical Studies," Ann. Oncol. 9:1053-1071
	A41	Ratner et al. (1998) "Ultraviolet Radiation-Induced Ubiquitination and Proteasomal Degradation of the Large Subunit of RNA Polymerase II," <i>J. Biolog. Chem.</i> 273:5184-5189

EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.



5	A42	Reed (1998) "Platinum-DNA Adduct, Nucleotide Excision Repair and Platinum Based Anti-Cancer Therapy," Cancer Treat Rev. Vol.24, pp.331-344
L	A43	Slapak et al. (1998) Harrison's Principles of Internal Medicine 14 th Edition, McGraw-Hill, NY, Chapter 86
	A44	Woynarowski et al. (1998) "Sequence- and Region-Specificity of Oxaliplatin Adducts in Naked and Cellular DNA," <i>Mol. Pharmacol.</i> 54:770-777
	A45	You et al. (1998) "Dual Effect of <i>erb</i> B-2 Depletion on the Regulation of DNA Repair and Cell Cycle Mechanisms in Non-SMall Cell Lung Cancer Cells," <i>Oncogene</i> 17:3177-3186
	A46	Akiyama et al. (1999) "Resistance to Cisplatin," Anticancer Drug Des. 14:143-151
-	A47	Cullinane et al. (1999) "Inhibition of RNA Polymerase II Transcription in Human Cell Extracts by Cisplatin DNA Damage," <i>Biochem.</i> 38:6204-6212
	A48	de Laat et al. (1999) "Molecular Mechanism of Nucleotide Excision Repair," Genes Dev. 13:768-785
	A49	Frit et al. (1999) "Transcription Factor IIH: A Key Player in the Cellular Response to DNA Damage," <i>Biochimie</i> 81:27-38
	A50	Koberle et al. (1999) "Defective Repair of Cisplatin-Induced DNA Damage Caused by Reduced XPA Protein in Testicular Germ Cell Tumours," <i>Curr. Biol.</i> 9:273-276
,	A51	Nehme et al. (1999) "Induction of JNK and c-Abi Signalling by Cisplatin and Oxaliplatin in Mismatch Repair- Proficient and –Deficicient Cells," <i>Br. J. Can.</i> 79:1104-1110
1	A52	Reardon et al. (1999) "Efficient Nucleotide Excision Repair of Cisplatin, Oxaliplatin, and Bis-aceto-ammine-dichloro- cyclohexylamine-platinum (IV) (JM216) Platinum Intrastrand DNA Diadducts," Can. Res. 59:3968-3971
•••	A53	Trimmer et al. (1999) "Cisplatin," Essays Biochem. 34:191-211
•	A54	Yu et al. (1999) "Pharmacokinetics and Tissue Disposition in Monkeys of an Antisense Oligonucleotide Inhibitor of Ha-Ras Encapsulated in Stealth Liposomes," Pharm. Res. 16:1309-1315
	A55	Agrawal et al. (2000) "Antisense Therapeutics: Is It As Simple As Complementary Base Recognition," Mol. Med. Today 6:72-81
/	A56	Andera et al. (2000) "Transcription Abnormalities Potentiate Apoptosis of Normal Human Fibroblasts," <i>Mol. Med.</i> 3:852-863
	A57	Dabholkar et al. (2000) "Increased mRNA Levels of Xeroderma Pigmentosum Complementation Group B (XPB) and Cockayne's Syndrome Complementation Group B (CSB) Without Increased mRNA Levels of Multidrug-Resistance Gene (MDR1) or Metallothionein-II (MT-II) in Platinum-Resistant Human Ovarian Cancer Tissue," <i>Biochem. Pharmacol.</i> 60:1611-1619
/	A58	de Gramont et al. (2000) "Leucovorin and Flurouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer," <i>J. Clin. Oncol.</i> 18:2938-2947
	A59	Hanawalt (2000) "The Bases for Cockayne Syndrome," Nature 405:415-416
	A60	Le Page et al. (2000) "Transcription-Coupled Repair of 8-oxoGuanine: Requirement for XPG, TFIIH, and CSB and Implications for Cockayne Syndrome," Cell 101:159-171
	A61	Misset et al. (2000) "Oxaliplatin Clinical Activity: A Review," Crit. Rev. Oncol. Hematol. 35:75-93
	A62	Nakatsu et al. (2000) "XAB2, A Novel Tetratricopeptide Repeat Protein Involved in Transcription-Coupled DNA Repair and Transcription," <i>JBC</i> 275:34931-34937
	A63	Ott et al. (2000) "Statistical Approaches to Gene Mapping," Am. J. Hum. Genet. 67:289-294
	A64	Pagnan et al. (2000) "Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD ₂ -Targeted Immunoliposomes: Antitumor Effects," <i>J. Natl. Can. Inst.</i> 92:253-261
(A65	Rockx et al. (2000) "UV-Induced Inhibition of Transcription Involves Repression of Transcription Initiation and Phosphorylation of RNA Polymerase II," <i>Proc. Natl. Acad. Sci. USA</i> 97:10503-10508
	A66	Seroz et al. (2000)"Cloning of a Human Homolog of the Yeast Nucleotide Excision Repair Gene MMS19 and Interation With Transcription Factor TFIIH Via the XPB and XPD Helicases," <i>Nucl. Acids Res.</i> 28:4506-4513

EXAMINER	DATE CONSIDERED		
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation			

if not conformance and not considered. Include copy with next communication to applicant.